Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Employees
123
Headquarters
Website
AMLX Metrics
BasicAdvanced
$1.5B
-
-$2.41
-0.45
-
Price and volume
Market cap
$1.5B
Beta
-0.45
52-week high
$16.96
52-week low
$2.60
Average daily volume
1.9M
Financial strength
Current ratio
8.723
Quick ratio
8.45
Long term debt to equity
3.155
Total debt to equity
3.551
Profitability
EBITDA (TTM)
-196.297
Gross margin (TTM)
37,961.04%
Net profit margin (TTM)
75,341.37%
Operating margin (TTM)
79,106.43%
Effective tax rate (TTM)
0.34%
Management effectiveness
Return on assets (TTM)
-46.74%
Return on equity (TTM)
-87.42%
Valuation
Price to revenue (TTM)
-4,433.667
Price to book
7.53
Price to tangible book (TTM)
7.53
Price to free cash flow (TTM)
-5.467
Free cash flow yield (TTM)
-18.29%
Free cash flow per share (TTM)
-2.592
Growth
Revenue change (TTM)
-100.08%
Earnings per share change (TTM)
-1.95%
3-year revenue growth (CAGR)
-4.40%
3-year earnings per share growth (CAGR)
-21.41%
Bulls say / Bears say
A U.S. FDA advisory committee voted 7-to-2 in favor of AMX0035 for ALS on September 8, resulting in a 70% jump in Amylyx shares and highlighting strong regulatory support for its lead therapy (Reuters)
On September 30, the FDA approved Relyvrio and Amylyx set its first-year price at $158,000, pointing to clear reimbursement prospects and a strong revenue outlook in the ALS market (Reuters)
Amylyx widened its pipeline by advancing avexitide for post-bariatric hypoglycemia after acquiring it from Eiger BioPharmaceuticals in 2024, expanding beyond neurodegenerative therapies (Reuters)
AMX0035 failed to show efficacy in a mid-stage trial for progressive supranuclear palsy, leading Amylyx to stop both the PSP program and its open-label extension, leaving a significant gap in the pipeline (Reuters)
In August, Amylyx announced it voluntarily withdrew Relyvrio from U.S. and Canadian markets in 2024 after a failed late-stage ALS trial, emphasizing past regulatory and efficacy setbacks that have strained commercial prospects (Reuters)
Amylyx’s late-stage pipeline is now centered on just two products—AMX0035 for Wolfram syndrome and avexitide for post-bariatric hypoglycemia—upping development risks due to limited diversification (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
AMLX News
AllArticlesVideos
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Business Wire2 months ago
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire2 months ago
Amylyx to stop development of rare brain disorder drug after trial failure
Reuters2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.5B as of October 26, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of October 26, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.45. This means that it has an inverse relation to market volatility.